Gilead
Contact information
Gilead Sciences, SL
Maria Rio, Directora General
C/ Via de los Poblados, 3.Cristalia Edificio 7/8 , Planta 6ª
Madrid
Madrid
913789830
913789841
Areas of activities
- A. Health Biotechnology
- Areas of activity
- Gene Therapy
- Therapeutic areas
- Cardiovascular diseases and circulatory system
- Genetic and rare diseases
- Infectious diseases
- Inflammatory diseases
- Oncology
- Digestive system and hepatology
- Respiratory and pulmonary system
Commissions
Gilead investigates, develops and commercializes innovative drugs in therapeutics areas with uncovered needs, with the objective to improve curation and surveillance rates in patients with severe infectious diseases.
Products and services
- HIV: Viread (Tenofovir disoproxil). Emtriva (Emtricitabine). Truvada (Tenofovir disoproxil and emtricitabine in a single tablet). Atripla (Tenofovir disoproxil, emtricitabine & efavirenz, one pill, once a day)
- Hepatitis B: Hepsera (Adefovir dipivoxil). Viread (Tenofovir disoproxil).
- Antifungal: Ambisome (Anphotericin B liposomic)
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Development phase |
|---|---|---|---|
| Vesatolimod | Biodrugs/ Drugs | Inmunología | P II |
| Trodelvy | Biodrugs/ Drugs | Oncología | P III |
| Selgantolimod | Biodrugs/ Drugs | P II | |
| Sacituzumab govitecan-hziy + pembrolizumab | Biodrugs/ Drugs | Oncología | P III |
| Sacituzumab govitecan-hziy + pembrolizumab | Biodrugs/ Drugs | Oncología | P III |
| Sacituzumab govitecan-hziy + pembrolizumab | Biodrugs/ Drugs | Oncología | P II |
| Sacituzumab govitecan-hziy + combinations | Biodrugs/ Drugs | Oncología | P II |
| Sacituzumab govitecan-hziy | Biodrugs/ Drugs | Oncología | P III |
| Sacituzumab govitecan-hziy | Biodrugs/ Drugs | Oncología | P III |
| Sacituzumab govitecan-hziy | Biodrugs/ Drugs | Oncología | P II |
| Obeldesivir | Biodrugs/ Drugs | P III | |
| MCL1 inhibitor (GS-9716) | Biodrugs/ Drugs | Oncología | P I |
| Magrolimab + chemotherapy/SG combinations | Biodrugs/ Drugs | Oncología | P II |
| Magrolimab + chemotherapy | Biodrugs/ Drugs | Oncología | P II |
| Magrolimab + chemotherapy/IO combinations | Biodrugs/ Drugs | Oncología | P II |
| Magrolimab + chemotherapy | Biodrugs/ Drugs | Oncología | P II |
| Magrolimab + azacitidine | Biodrugs/ Drugs | Oncología | P III |
| Magrolimab + azacitidine | Biodrugs/ Drugs | Enfermedades genéticas y raras | P III |
| Lenacapavir / bictegravir | Biodrugs/ Drugs | Inmunología | P III |
| Lenacapavir | Biodrugs/ Drugs | Inmunología | P II |
| Etrumadenant + zimberelimab combinations | Biodrugs/ Drugs | Oncología | P II |
| Domvanalimab + zimberelimab + chemotherapy | Biodrugs/ Drugs | Oncología | P III |
| Cilofexor / firsocostat / semaglutide combination | Biodrugs/ Drugs | P II | |
| CCR8 (GS-1811) | Biodrugs/ Drugs | Oncología | P I |
| Brexucabtagene autoleucel | Biodrugs/ Drugs | Oncología | P II |